Showing results (561-570 of 631) with videos related to

Sort By:
Pageof 64
Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Clinical and Translational Medicine|October 17, 2024
Single-cell transcriptional atlas of human breast cancers and model systemsJulia E Altman, Amy L Olex, Emily K Zboril, et al.
Vaccine|January 8, 2022
International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal diseaseR A Gladstone, L Siira, O B Brynildsrud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2025
The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial CancerErica V Carballo, Paula Gonzalez-Ericsson, Brian D Lehmann, et al.
Molecular Oncology|August 7, 2013
SPARCL1 suppresses metastasis in prostate cancerYuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
International Journal of Pediatric Otorhinolaryngology|November 11, 2023
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccinesA J Leach, N Wilson, B Arrowsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Science Translational Medicine|March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitorsJohanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
Pageof 64